2018 - Fellow, National Academy of Inventors
2014 - Fellow of the American Association for the Advancement of Science (AAAS)
Aptamer, RNA, Molecular biology, Gene and Cell biology are his primary areas of study. His Aptamer research integrates issues from In vitro, Small molecule, Antibody, Computational biology and Pharmacology. His Pharmacology research is multidisciplinary, relying on both Anticoagulant, Aptamer Technology and Factor IXa.
The various areas that Bruce A. Sullenger examines in his RNA study include Nucleic acid and DNA. His biological study spans a wide range of topics, including Cell culture and Transfection. His study in Cell biology is interdisciplinary in nature, drawing from both Agonist, Receptor, Cell and Glioma.
His main research concerns Aptamer, RNA, Molecular biology, Cell biology and Biochemistry. His Aptamer research is multidisciplinary, incorporating perspectives in Oligonucleotide, Systematic evolution of ligands by exponential enrichment, Pharmacology, Computational biology and Thrombin. In his research on the topic of Pharmacology, Heparin is strongly related with Anticoagulant.
His RNA study integrates concerns from other disciplines, such as DNA and Intron. His Molecular biology study incorporates themes from Cell, Integrin, Cancer research, In vitro and Transfection. His study ties his expertise on Receptor together with the subject of Cell biology.
Bruce A. Sullenger mainly investigates Aptamer, Cancer research, Nucleic acid, Cell biology and Cancer. The study incorporates disciplines such as Anticoagulant, Antibody, Pharmacology and Systematic evolution of ligands by exponential enrichment in addition to Aptamer. The concepts of his Cancer research study are interwoven with issues in Pancreatic cancer, Cancer cell, Metastasis, Triple-negative breast cancer and Prostate cancer.
Bruce A. Sullenger has researched Cell biology in several fields, including Native state, Reprogramming, Oligonucleotide and RNA. His RNA research integrates issues from Interferon, Nucleotide and Programmed cell death. The study incorporates disciplines such as Transfection and Transactivation in addition to Cancer.
His primary areas of investigation include Aptamer, Pharmacology, Antibody, Anticoagulant and Oligonucleotide. His Aptamer research is multidisciplinary, relying on both Epidermal growth factor receptor, Heparin, Native state, Cell biology and Cell sorting. His Transcription research extends to Pharmacology, which is thematically connected.
His studies in Anticoagulant integrate themes in fields like Hemostasis, Coagulation and Bioinformatics. His work in Oligonucleotide tackles topics such as Computational biology which are related to areas like Nucleic acid. His studies deal with areas such as Pancreatic cancer, Cancer cell, RNA, Extracellular and Tumor progression as well as Nucleic acid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
James O McNamara;Eran R Andrechek;Yong Wang;Kristi D Viles.
Nature Biotechnology (2006)
Aptamers: An Emerging Class of Therapeutics
Shahid M Nimjee;Christopher P Rusconi;Bruce A Sullenger.
Annual Review of Medicine (2005)
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
Bruce A. Sullenger;Humilidad F. Gallardo;Grace E. Ungers;Eli Gilboa.
In vivo activity of nuclease-resistant siRNAs
Juliana M. Layzer;Anton P. Mccaffrey;Alice K. Tanner;Zan Huang.
Notch promotes radioresistance of glioma stem cells
Jialiang Wang;Timothy P. Wakeman;Justin D. Lathia;Anita B. Hjelmeland.
Stem Cells (2009)
RNA aptamers as reversible antagonists of coagulation factor IXa.
Christopher P. Rusconi;Elizabeth Scardino;Juliana Layzer;George A. Pitoc.
Emerging clinical applications of RNA
Bruce A. Sullenger;Eli Gilboa.
Ribozyme-mediated repair of defective mRNA by targeted trans -splicing
Bruce A. Sullenger;Thomas R. Cech.
Antidote-mediated control of an anticoagulant aptamer in vivo.
Christopher P Rusconi;Joseph D Roberts;George A Pitoc;Shahid M Nimjee.
Nature Biotechnology (2004)
Developing aptamers into therapeutics
Rebekah R. White;Bruce A. Sullenger;Christopher P. Rusconi.
Journal of Clinical Investigation (2000)
Nucleic Acid Therapeutics
(Impact Factor: 4.244)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: